CAPTAIN STUDY: ASSOCIATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS WITH LUNG FUNCTION AND PATIENT-REPORTED OUTCOMES IN A LARGE RANDOMIZED PHASE III CLINICAL TRIAL

被引：0
|
作者：
Sule, Neal
Fowler, Andrew
Kerstjens, Huib
Kerwin, Edward
Lee, Laurie
Nathan, Robert
Oppenheimer, John
Pavord, Ian
Peachey, Guy
Tabberer, Maggie
Zarankaite, Agne
Manning, Michael
Millard, Mark
Mannino, David
Hanania, Nicola
机构：
来源：
CHEST | 2020年 / 158卷 / 04期
关键词：
D O I：
10.1016/j.chest.2020.08.072
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：35A / 38A
页数：4
相关论文
共 50 条
  • [21] Effect of apremilast on patient-reported outcomes in patients with moderate to severe plaque psoriasis in the ESTEEM 1 trial
    Armstrong, A. W.
    Griffiths, C.
    Tencer, T.
    Li, S.
    Zhang, F.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 67 - 67
  • [22] Effect of apremilast on patient-reported outcomes in patients with moderate to severe plaque psoriasis in the ESTEEM 1 trial
    Armstrong, April
    Griffiths, Christopher
    Tencer, Tom
    Li, Stan
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB231 - AB231
  • [23] LEBRIKIZUMAB IMPROVES CLINICAL MANIFESTATIONS AND PATIENT-REPORTED OUTCOMES IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: PHASE 2B STUDY RESULTS
    Ali, Z.
    Guttman-Yassky, E.
    Blauvelt, A.
    Eichenfield, L.
    Paller, A.
    Armstrong, A.
    Drew, J.
    Gopalan, R.
    Simpson, E.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 32 - 32
  • [24] Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis
    Simpson, Eric
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB167 - AB167
  • [25] Patient Advocates for Low-Income Adults with Moderate to Severe Asthma: A Randomized Clinical Trial
    Apter, Andrea J.
    Perez, Luzmercy
    Han, Xiaoyan
    Ndicu, Grace
    Localio, Anna
    Park, Hami
    Mullen, Alyssa N.
    Klusaritz, Heather
    Rogers, Marisa
    Cidav, Zuleyha
    Bryant-Stephens, Tyra
    Bender, Bruce G.
    Reisine, Susan T.
    Morales, Knashawn H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (10): : 3466 - +
  • [26] Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma
    Frix, A. N.
    Schleich, F.
    Paulus, V
    Guissard, F.
    Henket, M.
    Louis, R.
    BIOCHEMICAL PHARMACOLOGY, 2020, 179
  • [27] A RANDOMIZED PHASE 3 STUDY ASSESSING PATIENT-REPORTED OUTCOMES AND SAFETY OF RESLIZUMAB IN PATIENTS WITH ASTHMA WITH ELEVATED EOSINOPHILS.
    Maspero, J.
    Bjermer, L.
    Lemiere, C.
    Ciesielska, M.
    O'Brien, C.
    Zangrilli, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (05) : A21 - A21
  • [28] Harnessing Electronic Patient-Reported Outcomes (ePRO) in Routine Care to Promote Clinical Trial Enrollment: A Randomized Study
    Verdini, N. P.
    Bry, K. L.
    Bucknum, A. E.
    Baser, R. E.
    Lapen, K.
    Khan, A. J.
    Gomez, D. R.
    Braunstein, L. Z.
    Mao, J. J.
    Gillespie, E. F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S115 - S116
  • [29] Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
    Augustin, Matthias
    Lambert, Jo
    Zema, Carla
    Thompson, Elizabeth H. Z.
    Yang, Min
    Wu, Eric Q.
    Garcia-Horton, Viviana
    Geng, Ziqian
    Valdes, Joaquin M.
    Joshi, Avani
    Gordon, Kenneth B.
    JAMA DERMATOLOGY, 2020, 156 (12) : 1344 - 1353
  • [30] Isotonic Phase I Cancer Clinical Trial Design Utilizing Patient-Reported Outcomes
    Wages, Nolan A.
    Lin, Ruitao
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2025, 17 (01): : 36 - 45
12345